Literature DB >> 12190974

The global burden of epilepsy.

Matilde Leonardi1, T Bedirhan Ustun.   

Abstract

We briefly describe the Global Burden of Diseases (GBD) study, its goals, and some of its outcomes as related to neurologic and psychiatric disorders. The summary measure of population health DALYs (Disability Adjusted Life Years) are described, as well as the implications for neuropsychiatric disorders of changing health indicators and the move from mortality toward disability indicators. The pressing need for new measures for health is answered by the new WHO Classification of Functioning Disability and Health, ICF, and a brief summary of its basic principles is provided. Although a better understanding of the physical, social, and economic burden of epilepsy has moved this disorder higher on the world's agenda, epilepsy still has problems to be recognized as a public health priority. The implications of a shift toward considering the disability of epilepsy, as outlined in the the WHO World Health Report 2001, are important. The burden of epilepsy is high and, for the year 2000, accounts for approximately 0.5% of the whole burden of diseases in the world.

Entities:  

Mesh:

Year:  2002        PMID: 12190974     DOI: 10.1046/j.1528-1157.43.s.6.11.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  60 in total

1.  Dihydropyrimidinone positive modulation of delta-subunit-containing gamma-aminobutyric acid type A receptors, including an epilepsy-linked mutant variant.

Authors:  Ryan W Lewis; John Mabry; Jason G Polisar; Kyle P Eagen; Bruce Ganem; George P Hess
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

Review 2.  Global disparities in the epilepsy treatment gap: a systematic review.

Authors:  Ana-Claire Meyer; Tarun Dua; Juliana Ma; Shekhar Saxena; Gretchen Birbeck
Journal:  Bull World Health Organ       Date:  2009-09-25       Impact factor: 9.408

3.  Prevalence case-control study of epilepsy in three Burkina Faso villages.

Authors:  P Nitiéma; H Carabin; S Hounton; N Praet; L D Cowan; R Ganaba; C Kompaoré; Z Tarnagda; P Dorny; A Millogo
Journal:  Acta Neurol Scand       Date:  2012-01-31       Impact factor: 3.209

Review 4.  Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Authors:  Jair de Jesus Mari; Luís Fernando Tófoli; Cristiano Noto; Li M Li; Alessandra Diehl; Angélica M Claudino; Mario F Juruena
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

5.  Integrating artificial intelligence with real-time intracranial EEG monitoring to automate interictal identification of seizure onset zones in focal epilepsy.

Authors:  Yogatheesan Varatharajah; Brent Berry; Jan Cimbalnik; Vaclav Kremen; Jamie Van Gompel; Matt Stead; Benjamin Brinkmann; Ravishankar Iyer; Gregory Worrell
Journal:  J Neural Eng       Date:  2018-06-01       Impact factor: 5.379

6.  Multi-feature localization of epileptic foci from interictal, intracranial EEG.

Authors:  Jan Cimbalnik; Petr Klimes; Vladimir Sladky; Petr Nejedly; Pavel Jurak; Martin Pail; Robert Roman; Pavel Daniel; Hari Guragain; Benjamin Brinkmann; Milan Brazdil; Greg Worrell
Journal:  Clin Neurophysiol       Date:  2019-08-05       Impact factor: 3.708

Review 7.  Epilepsy treatment in sub-Saharan Africa: closing the gap.

Authors:  J H Chin
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

8.  Antiepileptic activity of preferential inhibitors of persistent sodium current.

Authors:  Lyndsey L Anderson; Christopher H Thompson; Nicole A Hawkins; Ravi D Nath; Adam A Petersohn; Sridharan Rajamani; William S Bush; Wayne N Frankel; Carlos G Vanoye; Jennifer A Kearney; Alfred L George
Journal:  Epilepsia       Date:  2014-05-23       Impact factor: 5.864

9.  Preterm birth and risk of epilepsy in Swedish adults.

Authors:  Casey Crump; Kristina Sundquist; Marilyn A Winkleby; Jan Sundquist
Journal:  Neurology       Date:  2011-10-04       Impact factor: 9.910

10.  Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.

Authors:  T D M Hill; M-G Cascio; B Romano; M Duncan; R G Pertwee; C M Williams; B J Whalley; A J Hill
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.